<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">healthcare</journal-id><journal-title-group><journal-title xml:lang="ru">Здравоохранение. Healthcare</journal-title><trans-title-group xml:lang="en"><trans-title>Healthcare</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1027-7218</issn><publisher><publisher-name>Republican Scientific and Practical Center for Medical Technologies, Informatization, Management and Health Economics</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">healthcare-204</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛЕКЦИИ И ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LECTURES AND REVIEWS</subject></subj-group></article-categories><title-group><article-title>Бета-адреноблокаторы: новое или хорошо известное старое?</article-title><trans-title-group xml:lang="en"><trans-title>Betaadrenoblockers: new or well-known old?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-1854-9672</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гальцова</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Galtsova</surname><given-names>O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гальцова Ольга Анатольевна — к. м. н., доцент кафедры клинической фармакологии и фармакотерапии </p><p>Пос. Лесной, 1, 223040, Минский р-н, Боровлянский с/с, 201, вблизи аг. Лесной. Сл. тел. +375 17 265-39-81. </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Захаренко</surname><given-names>А. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Zakharenko</surname><given-names>A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Минск</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Боровая</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Borovaya</surname><given-names>T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Минск</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Институт повышения квалификации и переподготовки кадров здравоохранения УО «Белорусский государственный медицинский университет»</institution><country>Belarus</country></aff><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>22</day><month>11</month><year>2025</year></pub-date><volume>1</volume><issue>10</issue><fpage>36</fpage><lpage>44</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гальцова О.А., Захаренко А.Г., Боровая Т.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Гальцова О.А., Захаренко А.Г., Боровая Т.В.</copyright-holder><copyright-holder xml:lang="en">Galtsova O., Zakharenko A., Borovaya T.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://healthcare.ejournal.by/jour/article/view/204">https://healthcare.ejournal.by/jour/article/view/204</self-uri><abstract><p>Сердечно-сосудистые заболевания (ССЗ) каждый год уносят более 4 млн жизней. В общем массиве различных лекарственных средств для лечения ССЗ отдельную нишу занимают β-адреноблокаторы. Уровень симпатической активности является независимым предиктором как общей, так и сердечно-сосудистой смертности.Несмотря на то что β-адреноблокаторы давно известны, они остаются актуальными в лечении различных заболеваний и в настоящее время, особенно у отдельных категорий пациентов (беременных, пациентов с хронической сердечной недостаточностью, острыми и хроническими коронарными синдромами, хронической болезнью почек).Проведен анализ современных данных литературы и рекомендаций, посвященных вопросам профилактики и лечения ССЗ с позиции использования β-адреноблокаторов.</p></abstract><trans-abstract xml:lang="en"><p>Cardiovascular diseases claim more than 4 million lives every year. In the general array of various drugs for the treatment of CVD, a separate niche is occupied by betaadrenoblockers. The level of sympathetic activity is an independent predictor of both total and cardiovascular mortality.Despite the fact that betaadrenoblockers have long been known, they remain relevant in the treatment of various diseases and at the present time, especially in certain categories of patients (pregnant women, patients with chronic heart failure, acute and chronic coronary syndromes, chronic kidney disease).The article analyzed the current literature and recommendations on the prevention and treatment of cardiovascular diseases from the perspective of the use of the article analyzed the current literature and recommendations on the prevention and treatment of cardiovascular diseases from the perspective of the use of betaadrenoblockers.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>β-адреноблокаторы</kwd><kwd>хроническая сердечная недостаточность</kwd><kwd>артериальная гипертензия</kwd><kwd>хроническая болезнь почек</kwd></kwd-group><kwd-group xml:lang="en"><kwd>betaadrenoblockers</kwd><kwd>chronic heart failure</kwd><kwd>arterial hypertension</kwd><kwd>chronic kidney disease</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Compelling indications should be listed for individual beta-blockers (due to diversity), not for the whole class / G. Koracevic, S. Micic, M. Stojanovic [et al.] // Current Vascular Pharmacology. — 2021. — Vol. 19, № 4. — P. 343—346.</mixed-citation><mixed-citation xml:lang="en">Compelling indications should be listed for individual beta-blockers (due to diversity), not for the whole class / G. Koracevic, S. Micic, M. Stojanovic [et al.] // Current Vascular Pharmacology. — 2021. — Vol. 19, № 4. — P. 343—346.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Beta-blocker efficacy across different cardiovascular indications : an umbrella review and metaanalytic assessment / O. J. Ziff, M. Samra, J. P. Howard [et al.] // BMC Medicine. — 2020. — Vol. 18, № 1. — DOI: 10.1186/s12916-020-01564-3.</mixed-citation><mixed-citation xml:lang="en">Beta-blocker efficacy across different cardiovascular indications : an umbrella review and metaanalytic assessment / O. J. Ziff, M. Samra, J. P. Howard [et al.] // BMC Medicine. — 2020. — Vol. 18, № 1. — DOI: 10.1186/s12916-020-01564-3.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Dulin, B. Beta-blockers in heart failure / B. Dulin, W. T. Abraham // American Journal of Cardiology. — 2004. — Vol. 93, Suppl. 1. — P. 1—82.</mixed-citation><mixed-citation xml:lang="en">Dulin, B. Beta-blockers in heart failure / B. Dulin, W. T. Abraham // American Journal of Cardiology. — 2004. — Vol. 93, Suppl. 1. — P. 1—82.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Feuerstein R., Yue T.L. Mechanisms of beta-blocker action in hypertension // Pharmacology. — 1994. — Vol. 48. — P. 385—391.</mixed-citation><mixed-citation xml:lang="en">Feuerstein R., Yue T.L. Mechanisms of beta-blocker action in hypertension // Pharmacology. — 1994. — Vol. 48. — P. 385—391.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Limited effect of systemic β-blockade on sympathetic outflow / J. Tank, A. Diedrich, C. Schroeder [et al.] // American Journal of Hypertension. — 2001. — Vol. 38, № 6. — P. 1377—1381.</mixed-citation><mixed-citation xml:lang="en">Limited effect of systemic β-blockade on sympathetic outflow / J. Tank, A. Diedrich, C. Schroeder [et al.] // American Journal of Hypertension. — 2001. — Vol. 38, № 6. — P. 1377—1381.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Перепеч, Н. Б. Место бета-адреноблокаторов в фармакотерапии артериальной гипертензии. Обзор литературы / Н. Б. Перепеч, В. Д. Шурыгина // Вестник Санкт-Петербургского университета. Сер. 11. Медицина. — 2014. — Т. 11, № 1. — С. 76—86.</mixed-citation><mixed-citation xml:lang="en">Перепеч, Н. Б. Место бета-адреноблокаторов в фармакотерапии артериальной гипертензии. Обзор литературы / Н. Б. Перепеч, В. Д. Шурыгина // Вестник Санкт-Петербургского университета. Сер. 11. Медицина. — 2014. — Т. 11, № 1. — С. 76—86.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Шляхто, Е. В. Вегетативная нервная система и артериальная гипертензия / Е. В. Шляхто, А. О. Конради, В. А. Цырлин. — СПб. : Медицинское изд-во, 2008. — 312 с.</mixed-citation><mixed-citation xml:lang="en">Шляхто, Е. В. Вегетативная нервная система и артериальная гипертензия / Е. В. Шляхто, А. О. Конради, В. А. Цырлин. — СПб. : Медицинское изд-во, 2008. — 312 с.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Механизмы антигипертензивного действия бета-адреноблокаторов / Э. В. Кулешова, Н. В. Кузьменко, М. Г. Плисс, В. А. Цырлин // Артериальная гипертензия. — 2021. — Т. 27, № 3. — С. 291—299.</mixed-citation><mixed-citation xml:lang="en">Механизмы антигипертензивного действия бета-адреноблокаторов / Э. В. Кулешова, Н. В. Кузьменко, М. Г. Плисс, В. А. Цырлин // Артериальная гипертензия. — 2021. — Т. 27, № 3. — С. 291—299.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Sympathetic outflow to muscles during treatment of hypertension with metoprolol / B. G. Wallin, G. Sundlof, E. Stromgren, H. Aberg // Hypertension. — 1984. — Vol. 6, № 4. — P. 557—562.</mixed-citation><mixed-citation xml:lang="en">Sympathetic outflow to muscles during treatment of hypertension with metoprolol / B. G. Wallin, G. Sundlof, E. Stromgren, H. Aberg // Hypertension. — 1984. — Vol. 6, № 4. — P. 557—562.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Arterial pressure lowering effect of chronic atenolol therapy in hypertension and vasoconstrictor sympathetic drive / J. Burns, D. A. Mary, A. F. Mackintosh // Hypertension. — 2004. — Vol. 44, № 4. — P. 454—458.</mixed-citation><mixed-citation xml:lang="en">Arterial pressure lowering effect of chronic atenolol therapy in hypertension and vasoconstrictor sympathetic drive / J. Burns, D. A. Mary, A. F. Mackintosh // Hypertension. — 2004. — Vol. 44, № 4. — P. 454—458.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Use of opposing reflex stimuli and heart rate variability to examine the effects of lipophilic and hydrophilic β-blockers on human cardiac vagal control / J. C. Vaile, J. Fletcher, M. Al-Ani [et al.] // Clinical Science (Lond). — 1999. — Vol. 97, № 5. — P. 585—593.</mixed-citation><mixed-citation xml:lang="en">Use of opposing reflex stimuli and heart rate variability to examine the effects of lipophilic and hydrophilic β-blockers on human cardiac vagal control / J. C. Vaile, J. Fletcher, M. Al-Ani [et al.] // Clinical Science (Lond). — 1999. — Vol. 97, № 5. — P. 585—593.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Acute and long-term studies of the mechanisms of action of β-blocking drugs in lowering blood pressure / K. O. Stumpe, R. Kolloch, H. Vetter [et al.] // American Journal of Medicine. — 1976. — Vol. 60, № 6. — P. 853—865.</mixed-citation><mixed-citation xml:lang="en">Acute and long-term studies of the mechanisms of action of β-blocking drugs in lowering blood pressure / K. O. Stumpe, R. Kolloch, H. Vetter [et al.] // American Journal of Medicine. — 1976. — Vol. 60, № 6. — P. 853—865.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Mechanism of renin inhibition by β adrenergic blocking agents / T. Saruta, T. Eguchi, R. Nakamura [et al.] // Japanese Heart Journal. — 1980. — Vol. 21, № 1. — P. 103—109.</mixed-citation><mixed-citation xml:lang="en">Mechanism of renin inhibition by β adrenergic blocking agents / T. Saruta, T. Eguchi, R. Nakamura [et al.] // Japanese Heart Journal. — 1980. — Vol. 21, № 1. — P. 103—109.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Multicenter evaluation of the hemodynamic effects of bisoprolol in patients with mild to moderate hypertension / L. M. Prisant, A. A. Carr, M. Desnoyers [et al.] // Journal of Clinical Pharmacology. — 1990. — Vol. 30, № 12. — P. 1096—1101.</mixed-citation><mixed-citation xml:lang="en">Multicenter evaluation of the hemodynamic effects of bisoprolol in patients with mild to moderate hypertension / L. M. Prisant, A. A. Carr, M. Desnoyers [et al.] // Journal of Clinical Pharmacology. — 1990. — Vol. 30, № 12. — P. 1096—1101.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Педли, Т. Гидродинамика крупных кровеносных сосудов / Т. Педли. — М. : Мир, 1983. — 400 с.</mixed-citation><mixed-citation xml:lang="en">Педли, Т. Гидродинамика крупных кровеносных сосудов / Т. Педли. — М. : Мир, 1983. — 400 с.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Согласованное мнение российских экспертов по оценке артериальной жесткости в клинической практике / Ю. А. Васюк, С. В. Иванова, Е. Л. Школьник [и др.] // Кардиоваскулярная терапия и профилактика. — 2016. — Т. 15, № 2. — C. 4—19.</mixed-citation><mixed-citation xml:lang="en">Согласованное мнение российских экспертов по оценке артериальной жесткости в клинической практике / Ю. А. Васюк, С. В. Иванова, Е. Л. Школьник [и др.] // Кардиоваскулярная терапия и профилактика. — 2016. — Т. 15, № 2. — C. 4—19.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Lund-Johansen, P. Haemodynamic long-term effects of metoprolol at rest and during exercise in essential hypertension / P. Lund-Johansen, O. J. Ohm // British Journal of Clinical Pharmacology. — 1977. — Vol. 4, № 2. — P. 147—151.</mixed-citation><mixed-citation xml:lang="en">Lund-Johansen, P. Haemodynamic long-term effects of metoprolol at rest and during exercise in essential hypertension / P. Lund-Johansen, O. J. Ohm // British Journal of Clinical Pharmacology. — 1977. — Vol. 4, № 2. — P. 147—151.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Morgan, T. Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance / T. Morgan, R. Snowden, L. Butcher // Journal of Cardiovascular Pharmacology. — 1987. — Vol. 11. — P. 124—129.</mixed-citation><mixed-citation xml:lang="en">Morgan, T. Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance / T. Morgan, R. Snowden, L. Butcher // Journal of Cardiovascular Pharmacology. — 1987. — Vol. 11. — P. 124—129.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Long-term reduction of peripheral resistance with celiprolol and effects on left ventricular mass / B. Trimarco, G. Lembo, N. De Luca [et al.] // Journal of International Medical Research. — 1988. — Vol. 16, № 1. — P. 62A—72A.</mixed-citation><mixed-citation xml:lang="en">Long-term reduction of peripheral resistance with celiprolol and effects on left ventricular mass / B. Trimarco, G. Lembo, N. De Luca [et al.] // Journal of International Medical Research. — 1988. — Vol. 16, № 1. — P. 62A—72A.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Башмаков, Ю. Э. Бета-адреноблокаторы и хроническая болезнь почек : литературный обзор / Ю. Э. Башмаков, А. Н. Федосеев, В. Е. Денисова // Качественная клиническая практика. — 2023. — № 4. — С. 58—77.</mixed-citation><mixed-citation xml:lang="en">Башмаков, Ю. Э. Бета-адреноблокаторы и хроническая болезнь почек : литературный обзор / Ю. Э. Башмаков, А. Н. Федосеев, В. Е. Денисова // Качественная клиническая практика. — 2023. — № 4. — С. 58—77.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Hundemer, G. L. β-blockers in hemodialysis: simple questions, complicated answers / G. L. Hundemer, M. M. Sood, M. Canney // Clinical Kidney Journal. — 2020. — Vol. 14, № 3. — P. 731—734.</mixed-citation><mixed-citation xml:lang="en">Hundemer, G. L. β-blockers in hemodialysis: simple questions, complicated answers / G. L. Hundemer, M. M. Sood, M. Canney // Clinical Kidney Journal. — 2020. — Vol. 14, № 3. — P. 731—734.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Segall, L. Heart failure in patients with chronic kidney disease : a systematic integrative review / L. Segall, I. Nistor, A. Covic // BioMed Research International. — 2014. — Vol. 2014. — DOI: 10.1155/2014/937398.</mixed-citation><mixed-citation xml:lang="en">Segall, L. Heart failure in patients with chronic kidney disease : a systematic integrative review / L. Segall, I. Nistor, A. Covic // BioMed Research International. — 2014. — Vol. 2014. — DOI: 10.1155/2014/937398.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Bakris, G. L. Beta blockers in the management of chronic kidney disease / G. L. Bakris, Р. Hart, Е. Ritz // Kidney International. — 2006. — Vol. 70, № 11. — P. 1905—1913.</mixed-citation><mixed-citation xml:lang="en">Bakris, G. L. Beta blockers in the management of chronic kidney disease / G. L. Bakris, Р. Hart, Е. Ritz // Kidney International. — 2006. — Vol. 70, № 11. — P. 1905—1913.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy / G. Cice, L. Ferrara, A. D'Andrea [et al.] // Journal of the American College of Cardiology. — 2003. — Vol. 41, № 9. — P. 1438—1444.</mixed-citation><mixed-citation xml:lang="en">Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy / G. Cice, L. Ferrara, A. D'Andrea [et al.] // Journal of the American College of Cardiology. — 2003. — Vol. 41, № 9. — P. 1438—1444.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Effects of beta-adrenergic antagonists in patients with chronic kidney disease / S. V. Badve, M. A. Roberts, C. M. Hawley [et al.] // Journal of the American College of Cardiology. — 2011. — Vol. 58, № 11. — P. 1152—1161.</mixed-citation><mixed-citation xml:lang="en">Effects of beta-adrenergic antagonists in patients with chronic kidney disease / S. V. Badve, M. A. Roberts, C. M. Hawley [et al.] // Journal of the American College of Cardiology. — 2011. — Vol. 58, № 11. — P. 1152—1161.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients / M. G. Shlipak, W. S. Browner, H. Noguchi [et al.] // The American Journal of Medicine. — 2001. — Vol. 110, № 6. — P. 425—433.</mixed-citation><mixed-citation xml:lang="en">Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients / M. G. Shlipak, W. S. Browner, H. Noguchi [et al.] // The American Journal of Medicine. — 2001. — Vol. 110, № 6. — P. 425—433.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Sinha, A. D. Clinical pharmacology of antihypertensive therapy / A. D. Sinha, R. Agarwal // Clinical journal of the American Society of Nephrology. — 2019. — Vol. 14, № 5. — P. 757—764.</mixed-citation><mixed-citation xml:lang="en">Sinha, A. D. Clinical pharmacology of antihypertensive therapy / A. D. Sinha, R. Agarwal // Clinical journal of the American Society of Nephrology. — 2019. — Vol. 14, № 5. — P. 757—764.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">β-Blocker use in long-term dialysis patients / K. C. Abbott, F. C. Trespalacios, L. Y. Agodoa [et al.] // Archives of internal medicine. — 2004. — Vol. 164, № 22. — P. 2465—2471.</mixed-citation><mixed-citation xml:lang="en">β-Blocker use in long-term dialysis patients / K. C. Abbott, F. C. Trespalacios, L. Y. Agodoa [et al.] // Archives of internal medicine. — 2004. — Vol. 164, № 22. — P. 2465—2471.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Catecholamine modulation of rapid potassium shifts during exercise / M. E. Williams, E. V. Gervino, R. M. Rosa [et al.] // The New England Journal of Medicine. — 1985. — Vol. 312, № 13. — P. 823—827.</mixed-citation><mixed-citation xml:lang="en">Catecholamine modulation of rapid potassium shifts during exercise / M. E. Williams, E. V. Gervino, R. M. Rosa [et al.] // The New England Journal of Medicine. — 1985. — Vol. 312, № 13. — P. 823—827.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Increase in serum potassium caused by beta-2 adrenergic blockade in terminal renal failure / P. Arrizabalaga, J. Montoliu, A. Martinez Vea [et al.] // Proceedings of the European Dialysis and Transplant Association. — 1983. — Vol. 20. — P. 572—576.</mixed-citation><mixed-citation xml:lang="en">Increase in serum potassium caused by beta-2 adrenergic blockade in terminal renal failure / P. Arrizabalaga, J. Montoliu, A. Martinez Vea [et al.] // Proceedings of the European Dialysis and Transplant Association. — 1983. — Vol. 20. — P. 572—576.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure / T. Hannedouche, P. Landais, B. Goldfarb [et al.] // BMJ. — 1994. — Vol. 309, № 6958. — P. 833—837.</mixed-citation><mixed-citation xml:lang="en">Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure / T. Hannedouche, P. Landais, B. Goldfarb [et al.] // BMJ. — 1994. — Vol. 309, № 6958. — P. 833—837.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics / A. J. Apperloo, D de Zeeuw, H. E. Sluiter, P. E. de Jong // BMJ. — 1991. — Vol. 303, № 6806. — P. 821—824.</mixed-citation><mixed-citation xml:lang="en">Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics / A. J. Apperloo, D de Zeeuw, H. E. Sluiter, P. E. de Jong // BMJ. — 1991. — Vol. 303, № 6806. — P. 821—824.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease / J. T. Wright, G. Bakris, T. Greene [et al.] // Journal of the American Medical Association. — 2002. — Vol. 288, № 19. — P. 2421—2431.</mixed-citation><mixed-citation xml:lang="en">Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease / J. T. Wright, G. Bakris, T. Greene [et al.] // Journal of the American Medical Association. — 2002. — Vol. 288, № 19. — P. 2421—2431.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) : a randomised trial // Lancet. — 1999. — Vol. 353, № 9146. — P. 9—13.</mixed-citation><mixed-citation xml:lang="en">The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) : a randomised trial // Lancet. — 1999. — Vol. 353, № 9146. — P. 9—13.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Effect of metoprolol CR/XL in chronic heart failure (MERIT-HF) // Lancet. — 1999. — Vol. 353, № 9169. — P. 2001—2007.</mixed-citation><mixed-citation xml:lang="en">Effect of metoprolol CR/XL in chronic heart failure (MERIT-HF) // Lancet. — 1999. — Vol. 353, № 9169. — P. 2001—2007.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) / M. D. Flather M. C. Shibata, A. J. S. Coats [et al.] // The European Heart Journal. — 2005. — Vol. 26, № 3. — P. 215—225.</mixed-citation><mixed-citation xml:lang="en">Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) / M. D. Flather M. C. Shibata, A. J. S. Coats [et al.] // The European Heart Journal. — 2005. — Vol. 26, № 3. — P. 215—225.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Eichhorn, E. J. The carvedilol prospective randomized cumulative survival (COPERNICUS) trial / E. J. Eichhorn, M. R. Bristow // Current Controlled Trials in Cardiovascular Medicine. — 2001. — Vol. 2, № 1. — P. 20—23.</mixed-citation><mixed-citation xml:lang="en">Eichhorn, E. J. The carvedilol prospective randomized cumulative survival (COPERNICUS) trial / E. J. Eichhorn, M. R. Bristow // Current Controlled Trials in Cardiovascular Medicine. — 2001. — Vol. 2, № 1. — P. 20—23.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">The effect of carvedilol on morbidity and mortality in patients with chronic heart failure / M. Packer, M. R. Bristow, J. N. Cohn [et al.] // New England Journal of Medicine. — 1996. — Vol. 334, № 21. — P. 1349—1355. — DOI:10.1056/NEJM199605233342101.</mixed-citation><mixed-citation xml:lang="en">The effect of carvedilol on morbidity and mortality in patients with chronic heart failure / M. Packer, M. R. Bristow, J. N. Cohn [et al.] // New England Journal of Medicine. — 1996. — Vol. 334, № 21. — P. 1349—1355. — DOI:10.1056/NEJM199605233342101.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment / Writing Committee ; T. M. Maddox, L. J. James, L. A. Allen [et al.] // Journal of the American College of Cardiology. — 2021. — Vol. 77, № 6. — P. 772—810.</mixed-citation><mixed-citation xml:lang="en">2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment / Writing Committee ; T. M. Maddox, L. J. James, L. A. Allen [et al.] // Journal of the American College of Cardiology. — 2021. — Vol. 77, № 6. — P. 772—810.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure / A. Hjalmarson, S. Goldstein, B. Fagerberg [et al.] // Journal of the American Medical Association. — 2000. — Vol. 283, № 10. — P. 1295—1302.</mixed-citation><mixed-citation xml:lang="en">Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure / A. Hjalmarson, S. Goldstein, B. Fagerberg [et al.] // Journal of the American Medical Association. — 2000. — Vol. 283, № 10. — P. 1295—1302.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure / Gattis W.A., Ch. M. O'Connor, J. D. Leimberger [et al.] // American Journal of Cardiology. — 2003. — Vol. 91, № 2. — P. 169—174.</mixed-citation><mixed-citation xml:lang="en">Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure / Gattis W.A., Ch. M. O'Connor, J. D. Leimberger [et al.] // American Journal of Cardiology. — 2003. — Vol. 91, № 2. — P. 169—174.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Protective effects of bisoprolol against myocardial injury and pulmonary dysfunction in patients with chronic heart failure / S. Toyoda, A. Haruyama, Sh. Inami [et al.] // International Journal of Cardiology. — 2017. — Vol. 226. — P. 71—76.</mixed-citation><mixed-citation xml:lang="en">Protective effects of bisoprolol against myocardial injury and pulmonary dysfunction in patients with chronic heart failure / S. Toyoda, A. Haruyama, Sh. Inami [et al.] // International Journal of Cardiology. — 2017. — Vol. 226. — P. 71—76.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension / T. Taniguchi, T. Ohtani, I. Mizote [et al.] // Journal of Cardiology. — 2013. — Vol. 61, № 6. — P. 417—422.</mixed-citation><mixed-citation xml:lang="en">Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension / T. Taniguchi, T. Ohtani, I. Mizote [et al.] // Journal of Cardiology. — 2013. — Vol. 61, № 6. — P. 417—422.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction / S. D. Solomon, J. J. V. McMurray, I. S. Anand [et al.] // New England Journal of Medicine. — 2019. — Vol. 381, № 17. — P. 1609—1620.</mixed-citation><mixed-citation xml:lang="en">Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction / S. D. Solomon, J. J. V. McMurray, I. S. Anand [et al.] // New England Journal of Medicine. — 2019. — Vol. 381, № 17. — P. 1609—1620.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction / J. P. Ferreira, J. Butler, F. Zannad [et al.] // Journal of the American College of Cardiology. — 2022. — Vol. 79, № 12. — P. 1129—1137.</mixed-citation><mixed-citation xml:lang="en">Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction / J. P. Ferreira, J. Butler, F. Zannad [et al.] // Journal of the American College of Cardiology. — 2022. — Vol. 79, № 12. — P. 1129—1137.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality / D. N. Silverman, T. B. Plante, M. Infeld [et al.] // JAMA Network Open. — 2019. — Vol. 2, № 12. — DOI: 10.1001/jamanetworkopen.2019.16598.</mixed-citation><mixed-citation xml:lang="en">Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality / D. N. Silverman, T. B. Plante, M. Infeld [et al.] // JAMA Network Open. — 2019. — Vol. 2, № 12. — DOI: 10.1001/jamanetworkopen.2019.16598.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Impact of sex and myocardial function on association of obesity with mortality in Asian patients with acute heart failure / C. S. Park, un-Bean Park, Jin Joo Park [et al.] // BMJ Open. — 2020. — Vol. 10, № 2. — DOI: 10.1136/bmjopen-2019-031608.</mixed-citation><mixed-citation xml:lang="en">Impact of sex and myocardial function on association of obesity with mortality in Asian patients with acute heart failure / C. S. Park, un-Bean Park, Jin Joo Park [et al.] // BMJ Open. — 2020. — Vol. 10, № 2. — DOI: 10.1136/bmjopen-2019-031608.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Dar, J. A. Beta Blockers in Contemporary Cardiology / J. A. Dar, J. R. Jacob // Korean Circulation Journal. — 2024. — Vol. 54, № 4. — P. 165—171.</mixed-citation><mixed-citation xml:lang="en">Dar, J. A. Beta Blockers in Contemporary Cardiology / J. A. Dar, J. R. Jacob // Korean Circulation Journal. — 2024. — Vol. 54, № 4. — P. 165—171.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Роль бета-блокаторов в лечении сердечно-сосудистых заболеваний / В. С. Чулков, М. З. Гасанов, О. В. Азовцева [и др.] // Медицинский совет. — 2024. — № 16. — С. 28—36.</mixed-citation><mixed-citation xml:lang="en">Роль бета-блокаторов в лечении сердечно-сосудистых заболеваний / В. С. Чулков, М. З. Гасанов, О. В. Азовцева [и др.] // Медицинский совет. — 2024. — № 16. — С. 28—36.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
